{"success":true,"data":{"pressRelease":{"id":"13933","rtpr_id":"nNFC7hmRrl","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA","author":"Newsfile Corp","published_at":"2026-04-29T21:27:13.912Z","article_body":"New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a\nglobal investor rights law firm, reminds purchasers of securities of Atara\nBiotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026,\ninclusive (the \"Class Period\"), of the important May 22, 2026 lead plaintiff\ndeadline.\n\nSO WHAT: If you purchased Atara securities during the Class Period you may be\nentitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Atara class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 22, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many\nof the firm's attorneys have been recognized by Lawdragon and Super Lawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, throughout the Class Period,\ndefendants made false and/or misleading statements and/or failed to disclose\nthat: (1) certain manufacturing issues, as well as deficiencies inherent in\nthe ALLELE study, made it unlikely that the U.S. Food and Drug Administration\n(\"FDA\") would approve the tabelecleucel Biologics License Application (\"BLA\");\n(2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the\naforementioned manufacturing issues also subjected Atara to a heightened risk\nof regulatory scrutiny, as well as jeopardized its ongoing clinical trials;\n(4) all the foregoing was likely to have a significant negative impact on\nAtara's business and financial condition; and (5) as a result, defendants'\npublic statements were materially false and/or misleading at all relevant\ntimes. When the true details entered the market, the lawsuit claims that\ninvestors suffered damages.\n\nTo join the Atara class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295036","article_body_html":"","raw_payload":{"data":{"id":"nNFC7hmRrl","title":"ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA","author":"Newsfile Corp","ticker":"ATRA","created":"2026-04-29T21:27:13.912Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a\nglobal investor rights law firm, reminds purchasers of securities of Atara\nBiotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026,\ninclusive (the \"Class Period\"), of the important May 22, 2026 lead plaintiff\ndeadline.\n\nSO WHAT: If you purchased Atara securities during the Class Period you may be\nentitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWHAT TO DO NEXT: To join the Atara class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than May 22, 2026. A\nlead plaintiff is a representative party acting on behalf of other class\nmembers in directing the litigation.\n\nWHY ROSEN LAW: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer recognition.\nMany of these firms do not actually handle securities class actions, but are\nmerely middlemen that refer clients or partner with law firms that actually\nlitigate the cases. Be wise in selecting counsel. The Rosen Law Firm\nrepresents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved, at that time, the largest ever securities class action\nsettlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS\nSecurities Class Action Services for number of securities class action\nsettlements in 2017. The firm has been ranked in the top 4 each year since\n2013 and has recovered hundreds of millions of dollars for investors. In 2019\nalone the firm secured over $438 million for investors. In 2020, founding\npartner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many\nof the firm's attorneys have been recognized by Lawdragon and Super Lawyers.\n\nDETAILS OF THE CASE: According to the lawsuit, throughout the Class Period,\ndefendants made false and/or misleading statements and/or failed to disclose\nthat: (1) certain manufacturing issues, as well as deficiencies inherent in\nthe ALLELE study, made it unlikely that the U.S. Food and Drug Administration\n(\"FDA\") would approve the tabelecleucel Biologics License Application (\"BLA\");\n(2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the\naforementioned manufacturing issues also subjected Atara to a heightened risk\nof regulatory scrutiny, as well as jeopardized its ongoing clinical trials;\n(4) all the foregoing was likely to have a significant negative impact on\nAtara's business and financial condition; and (5) as a result, defendants'\npublic statements were materially false and/or misleading at all relevant\ntimes. When the true details entered the market, the lawsuit claims that\ninvestors suffered damages.\n\nTo join the Atara class action, go to\nhttps://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq.\ntoll-free at 866-767-3653 or email case@rosenlegal.com for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm, on Twitter:\nhttps://twitter.com/rosen_firm or on Facebook:\nhttps://www.facebook.com/rosenlawfirm/.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\n-------------------------------\n\nContact Information:\n\nLaurence Rosen, Esq.\nPhillip Kim, Esq.\nThe Rosen Law Firm, P.A.\n275 Madison Avenue, 40th Floor\nNew York, NY 10016\nTel: (212) 686-1060\nToll Free: (866) 767-3653\nFax: (212) 202-3827\ncase@rosenlegal.com\nwww.rosenlegal.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295036"},"type":"article","timestamp":"2026-04-29T21:27:13.967672297Z","server_sent_at_ms":1777498033967},"received_at":"2026-04-29T21:27:14.021Z","source_url":"https://www.newsfilecorp.com/release/295036"},"analysis":{"id":"10846","press_release_id":"13933","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["allegations that regulatory prospects for lead asset tabelecleucel were overstated","allegations of undisclosed manufacturing issues"],"eventType":"legal_litigation","narrative":"Rosen Law Firm announced a securities class action against Atara Biotherapeutics for investors who purchased shares between May 20, 2024 and January 9, 2026.\n\nThe lawsuit alleges defendants made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely.\n\nInvestors have until May 22, 2026 to seek appointment as lead plaintiff in the litigation.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{"customDimensions":{"class_period_end":"January 9, 2026","class_period_start":"May 20, 2024","lead_plaintiff_deadline":"May 22, 2026"}},"quotedText":"manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the U.S. Food and Drug Administration (\"FDA\") would approve the tabelecleucel Biologics License Application (\"BLA\")","namedEntities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["tabelecleucel"],"companies":[{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA"},{"name":"Rosen Law Firm, P.A."}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Securities class action filed alleging misleading statements regarding FDA approval prospects for lead asset tabelecleucel. While serious, securities fraud litigation is common for clinical-stage biotechs and the binary regulatory risk was already realized (implied by the class period end date)."},"tickerRelevance":{"others":[],"primary":"ATRA"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid cap biotech","eventGravity":"standard securities class action notice","sectorWeight":"biotech litigation is common","householdBrandBoost":0}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Rosen Law Firm announced a securities class action against Atara Biotherapeutics for investors who purchased shares between May 20, 2024 and January 9, 2026.\n\nThe lawsuit alleges defendants made false statements regarding manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely.\n\nInvestors have until May 22, 2026 to seek appointment as lead plaintiff in the litigation.","key_figures":{"customDimensions":{"class_period_end":"January 9, 2026","class_period_start":"May 20, 2024","lead_plaintiff_deadline":"May 22, 2026"}},"named_entities":{"people":[{"name":"Laurence Rosen","role":"Founding Partner"},{"name":"Phillip Kim","role":"Attorney"}],"products":["tabelecleucel"],"companies":[{"name":"Atara Biotherapeutics, Inc.","ticker":"ATRA"},{"name":"Rosen Law Firm, P.A."}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-30T00:45:33.954Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-mid cap biotech","eventGravity":"standard securities class action notice","sectorWeight":"biotech litigation is common","householdBrandBoost":0}},"durationMs":37593,"modelName":"glm-4.7"}}